We all love a growing dividend and one of the most popular indices that cover the best dividend growth stocks is the S&P 500 Dividend Aristocrats index.
The index has currently 54 constituents. My goal in this article is to show you the currently cheapest stocks from the Dividend Aristocrats Index with current buy or better ratings.
I know, it�� a little bit easy to trust others work but the high-quality dividend stocks are already discovered. The only thing we must do is to screen the current valuations and market opinions.
Only twelve stocks fulfilled both, a forward P/E below 15 combined with a buy or better rating by brokerage firms. Half of the results have a projected double-digit mid-term earnings growth forecast.
I really like Dividend Aristocrats but because of the highly predictable business model and well known asset class, most of them are no longer cheap. Only eighteen stocks have an expected P/E under 15! That�� only one third of the full database and only around 20 percent of all Aristocrats are recommended to buy.
Top 10 Cheapest Stocks To Own For 2015: Pharmerica Corporation(PMC)
Pharmerica Corporation operates as an institutional pharmacy services company in the United States. It offers services to healthcare facilities and provides management pharmacy services to hospitals. The company purchases, repackages, and dispenses prescription and non-prescription pharmaceuticals in accordance with physician orders and delivers such medication to healthcare facilities for administration to individual patients and residents. It also provides consultant pharmacist services for customers to comply with the federal and state regulations applicable to nursing homes; and medical records services. In addition, the company offers various ancillary services, such as infusion therapy products and services; and hospital pharmacy management services, including hospital pharmacy operations, regulatory and financial management services, and clinical pharmacy programs to various hospitals. PharMerica Corporation operates approximately 95 institutional pharmacies in 44 s tates and provides pharmacy management services to 91 hospitals. Its customers primarily include institutional healthcare providers, such as skilled nursing facilities, nursing centers, assisted living facilities, hospitals, and other long-term alternative care settings. The company is headquartered in Louisville, Kentucky.
Advisors' Opinion:- [By Josh Arnold]
PharMerica Corporation (PMC) is a pharmacy services company that operates in several segments in the US. The company offers services to healthcare facilities, pharmacy management services and specialty infusion to patients outside of hospitals. PMC's primary customers are assisted living centers, hospitals, and other long term care facilities. The company services just under 200 locations in 45 states in the US and produces about $1.7 billion in annual revenue. With shares near the bottom of their 52 week range following a nasty selloff, is there any value in PMC or is it a classic trap? I'll argue here that PMC's structural tailwinds for earnings including demographics and consumer preference shifts will increase PMC's ability to convert revenue into profit and drive the stock higher.
- [By Sean Williams]
What: Shares of PharMerica (NYSE: PMC ) , a pharmacy services company, jumped as much as 11% after reporting better-than-expected first-quarter results.
Top 10 Cheapest Stocks To Own For 2015: AVG Technologies NV (AVG)
AVG Technologies N.V. (AVG), incorporated on March 3, 2011, provides software and online services. The Company is primarily engaged in the development and sale of Internet security software and online service solutions branded under the AVG name. The Company�� solutions include software and online services, include security, personal computer (PC) management, online backup and other products. As of December 31, 2011, the Company had approximately 15 million subscription users. AVG�� portfolio consists of Anti-Virus suite, Internet Security suite, Premium Security suite, AVG Mobilation, AVG Threatlabs, Family Safety, TuneUp Utilities and PC Tuneup, LiveKive and MultiMi. On January 4, 2011, the Company acquired DroidSecurity Ltd. On March 3, 2011, the Company established AVG Holding Cooperatief U.A. On May 18, 2011, the Company acquired iMedix Web Technologies Ltd. In August 2011, it acquired TuneUp Software GmbH. On August 19, 2011, AVG Technologies GER GmbH acquired TuneUp Software GmbH. On October 31, 2011, AVG Technologies Holdings B.V. acquired AVG Distribution Switzerland AG. In November 2011, the Company acquired Bsecure Solutions, Inc. On January 13, 2012, AVG Technologies USA, Inc. acquired OpenInstall, Inc. In May 2013, AVG Technologies NV acquired online privacy organisation PrivacyChoice.
The Company�� products include AVG Internet Security, AVG Anti-Virus, AVG Email Server Edition, AVG File Server Edition, AVG Linux Server Edition, AVG Rescue CD and AVG Remote Administration. The Company�� subsidiaries include AVG Technologies USA Inc., AVG Technologies CZ, s.r.o., AVG Technologies UK Ltd, AVG Exploit Prevention Labs, Inc., AVG Technologies GER, GmbH, AVG Technologies FRA SAS, AVG Technologies HK, Limited, AVG (Beijing) Internet Security Technologies Company Limited, AVG Mobile Technologies Ltd, AVG Netherlands B.V., AVG Ecommerce CY Ltd, AVG Technologies Holding B.V., TuneUp Software GmbH, TuneUp Distribution GmbH, TuneUp Corporation and AVG Distribution Switzerland AG! .
The Company competes with Microsoft, Google, Apple, Qihoo, Tencent, Facebook, UniBlue, Symantec, Trend Micro, Avast!, Avira, Symantec, Carbonite, Dropbox, Intel Corporation, Trend Micro, Eset, Kaspersky Labs, Panda Software, Sophos, Rising, Kingsoft, Check Point and F-Secure.
Advisors' Opinion:- [By Igor Novgorodtsev]
InterActiveCorp (IACI) bought Ask.com for $1.85 billion in 2005. The new Perion will be worth only about 40% of that. After the merger, Perion will leapfrog its much larger rivals: Babylon and AVG (AVG). Finally, Perion should be able to increase its operating margins as it can spread its SG&A costs over a much larger base (Conduit EBITDA margin is 32% vs. Perion's 23%). Perion will keep its senior management team intact: Josef Mandelbaum will remain its CEO and Yacov Kaufman its CFO. Perion has successfully orchestrated a roll-up acquisitions of privately-held Sweetpacks and Smilebox, so I have high confidence that they know how to integrate a new business.
- [By Seth Jayson]
AVG Technologies (NYSE: AVG ) reported earnings on April 24. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended March 31 (Q1), AVG Technologies beat expectations on revenues and crushed expectations on earnings per share. - [By MONEYMORNING]
For instance, in the March 15 Private Briefing report, "Double Your Money With this Cyber-Hacking of America Stock," we recommended AVG Technologies NV (NYSE: AVG), an Amsterdam-based cybersecurity whose shares we believed were good for a 100% gain in a year.
Best US Companies To Watch In Right Now: ITT Industries Inc.(ITT)
ITT Corporation designs, manufactures, and sells a range of engineered products, and provides related services worldwide. Its Defense & Information Solutions segment develops tactical communications equipment, electronic warfare and force protection equipment, radar systems, integrated structures equipment, and imaging and sensor equipment, including night vision goggles, as well as weather, location, surveillance, and other related technologies for military and government agencies. It also provides services comprising air traffic management, information and cyber solutions, large-scale systems engineering, and integration and defense technologies; satellite-based imaging payloads for intelligence, surveillance, and reconnaissance solutions; and high-resolution commercial imaging systems with earth and space science applications, climate and environmental monitoring sensors and systems, and GPS navigation and software applications designed for image and data processing and dissemination. The company?s Fluid Technology segment provides water transport and wastewater treatment systems, pumps and related technologies, and other water and fluid control products with municipal, residential, commercial, and industrial applications. Its Motion & Flow Control segment manufactures shock absorbers and brake friction materials for the transportation industry; switch applications for the industrial and aerospace industries; electrical connectors used in telecommunications, computers, aerospace, medical, and industrial applications; and a range of pumps and tailored products for marine, food and beverage, and general industrial markets. The company was formerly known as ITT Industries, Inc. and changed its name to ITT Corporation in July 2006. ITT Corporation was founded in 1920 and is based in White Plains, New York.
Advisors' Opinion:- [By MONEYMORNING]
This 85-year-old forest products company operates as a Real Estate Investment Trust (REIT) after being first acquired, then later spun off, by ITT Corp. (NYSE: ITT).
- [By Aaron Levitt]
Spun-off from industrial giant ITT (ITT) a few years ago, Xylem (XYL) could be a great starting point for investors looking at water stocks. Aside from its cool and appropriate name, XYL provides host of equipment — pumps, controllers and filtration devices — for wastewater treatment plants across the globe.
- [By Will Ashworth]
As for the other stocks in the portfolio, you can’t ignore the performance of both Apollo (APO) and ITT Corp. (ITT).
It’s been a busy year for private equity firm Apollo Global Management, which got the Twinkie back on grocery store shelves in July. Carried interest income more than doubled in the first six months of the year to $1.4 billion.
- [By Stephen Simpson, CFA]
This is a logical deal for SKF on multiple fronts. For starters, Kaydon will meaningfully expand the company's U.S. presence - something it could have done on its own eventually, but certainly not without spending money. With that, there is the possibility of using Kaydon's existing U.S. footprint to sell more SKF products and further trouble rivals like RBC Bearings (ROLL) and ITT (ITT).
Top 10 Cheapest Stocks To Own For 2015: Embarr Downs Inc (EMBR)
Embarr Downs, Inc. is a development-stage company. The Company's business is the buying, selling and racing of thoroughbreds that can race in the allowance and stakes levels of thoroughbred racing. The Company intends to acquire 4-6 horses in its claiming division before acquiring horses for its allowance/stakes division. These 4-6 horses will provide the Company with revenue and a foundation to build out a stakes level stable. The Company�� main focus will be acquiring horses that will be capable of racing in stake races throughout the Country. Advisors' Opinion:- [By Peter Graham]
Small cap stocks IDGlobal Corp (OTCMKTS: IDGC), Embarr Downs Inc (OTCMKTS: EMBR) and SourcingLink.net, Inc (OTCMKTS: SNET) have been getting some extra attention in various investment newsletters or investor alerts lately as at least two of these stocks have been the subject of paid promotions or other types of investor relations activities. Of course, there is nothing wrong with properly disclosed promotions or investor relations activities. But just how hot are these two small cap stocks? Here is a closer look and a quick reality check:
Top 10 Cheapest Stocks To Own For 2015: Violin Memory Inc (VMEM)
Violin Memory, Inc., incorporated on March 9, 2005, is pioneering a new class of flash-based storage systems that are designed to bring storage performance in-line with high-speed applications, servers and networks. The Company�� Flash Memory Arrays are specifically designed at each level of the system architecture starting with memory and optimized through the array to leverage the inherent capabilities of flash memory and meet the sustained requirements of business-critical applications, virtualized environments and Big Data solutions in enterprise data centers. The Company�� Velocity Peripheral Component Interconnect Express (PCIe), Flash Memory Cards leverage its persistent memory-based architecture in servers and are optimized for applications that require continuous access to quantities of low latency persistent memory located directly in servers.
The Company�� storage systems are based on a four-layer hardware architecture, which is integrated with its Violin Memory Operating System (vMOS), software stack to optimize the management of flash memory at each level of its system architecture. The Company�� Velocity PCIe Flash Memory Cards leverage its expertise in persistent memory-based storage and controller design, as well as its vMOS software stack, to offer a differentiated architecture in a deployable PCIe form factor.
Advisors' Opinion:- [By Eric Volkman]
Getty Images/Cultura As more than a few finance industry professionals will happily brag, 2013 was a banner year for initial public offerings with 156 new stocks coming to market -- the most since 2007 -- collectively reaping the issuers aggregate proceeds of more than $38 billion. We went over the most recognizable members of this year's rookie class in "The 5 Most Unfortgettable IPOs of 2013." But in a big pool of 156 companies, there are bound to be at least a few struggling fish. Here, then, is a selection of five from the class of 2013 that are getting seriously lapped by their peers. 1. Prosensa (RNA) This Dutch clinical-stage biopharmaceutical firm had a strong debut when it listed on the Nasdaq in late June. The stock's offer price of $13 zoomed to close at over $19 on the first day of trading. But bad news was waiting around the corner; less than three months later, the shares tanked by more than 70 percent after the company announced that the muscular dystrophy treatment (drisapersen) it was developing in partnership with GlaxoSmithKline (GLAXF), did not hit its primary endpoint in late-stage trials. That one-day free fall saw the stock swoon from $24 per share to barely over $7. Since then, shares have slipped even further, and can currently be had for less than $5. 2. Violin Memory (VMEM) As a provider of high-speed data storage solutions, this company should be well in tune with current IT needs. But it fell flat from the beginning -- on its first day of trading the stock closed slightly over $7 a share, after pricing at $9. Worse was to come when the firm reported its first quarterly results as a publicly traded entity. While revenue advanced nearly 40 percent on a year-over-year basis, that couldn't cover the gaping hole of a bottom line loss totaling $34 million (a figure, by the way, significantly higher than the top line number of $28 million). The already-sinking shares continued to dive, bottoming at just over $2.50 per share. The re
Top 10 Cheapest Stocks To Own For 2015: Merrimack Pharmaceuticals Inc (MACK)
Merrimack Pharmaceuticals, Inc., incorporated in 1993, is a biopharmaceutical company discovering, developing and preparing to commercialize medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. The Company�� product candidates include MM-398, MM-121, MM-111, MM-302 and MM-151. As of June 31, 2011, the Company owned approximately 74% interest of Silver Creek.
The Company�� Network biology is an interdisciplinary approach to drug discovery and development that enables the Company to build functional and predictive computational models of biological systems based on quantitative, kinetic, multiplexed biological data. The Company provides its scientists with insights into how the complex molecular interactions that occur within cell signaling pathways, or networks, regulate cell decisions and how dysfunction within these networks leads to disease. The Company applies network biology throughout the research and development process, including for target identification, lead compound design and optimization, diagnostic discovery, in vitro and in vivo predictive development and the design of clinical trial protocols.
MM-398
MM-398 is a stable nanotherapeutic encapsulation, or enclosed sphere carrying an active drug, of the marketed chemotherapy drug irinotecan. MM-398 achieved its primary efficacy endpoints in Phase 2 clinical trials in pancreatic and gastric cancer. In an open label, single arm Phase 2 clinical trial of MM-398 as a monotherapy in 40 metastatic pancreatic cancer patients who had previously failed treatment with gemcitabine, patients treated with MM-398 achieved median overall survival of 22.4 weeks. Additionally, 20% of the patients in this Phase 2 trial survived for more than one year, and the Company observed a disease control rate, meaning patients exhibited stable disease or partial or complete response to treatment, of 47.5% at six weeks.
The Company focuses on initiati! ng a Phase 3 clinical trial of MM-398 for the treatment of patients with metastatic pancreatic cancer who have previously failed treatment with gemcitabine. The trial is expected to enroll approximately 250 patients and is designed to compare the efficacy of MM-398 as a monotherapy against the combination of the chemotherapy drugs fluorouracil, or 5-FU, and leucovorin. There are multiple ongoing Phase 1 and Phase 2 clinical trials of MM-398. In July 2011, the United States Food and Drug Administration (FDA) granted MM-398 orphan drug designation for the treatment of pancreatic cancer.
MM-121
MM-121 is a fully human monoclonal antibody that targets ErbB3, a cell surface receptor, or protein attached to the cell membrane that mediates communication inside and outside the cell, that the Company�� network biology approach identified as a target in a range of cancers. A monoclonal antibody is a type of protein normally produced by cells of the immune system that binds to just one epitope, or chemical structure, on a protein or other structure. MM-121 is designed to inhibit cancer growth directly, restore sensitivity to drugs to which a tumor has become resistant and delay the development of resistance of a tumor to other agents. In collaboration with Sanofi, the Company focuses on testing MM-121 in combination with both chemotherapies and other targeted agents across a range of spectrum of solid tumors, including lung, breast and ovarian cancers. The Company partnered MM-121 with Sanofi after it initiated Phase 1 clinical development of the product candidate.
MM-111
MM-111 is a bispecific antibody designed to target cancer cells that are characterized by overexpression of the ErbB2 cell surface receptor, also referred to as HER2. A bispecific antibody is a type of antibody that is able to bind simultaneously to two distinct proteins or epitopes. The Company�� network biology approach identified that ligand-induced signaling through the complex of ErbB2 ! (HER2) an! d ErbB3 is a promoter of tumor growth and survival than previously appreciated.
MM-302
MM-302 is a nanotherapeutic encapsulation of doxorubicin with attached antibodies that are designed to target MM-302 to cells that over express the ErbB2 (HER2) receptor. The Company is conducting a Phase 1 clinical trial of MM-302 in patients with advanced ErbB2 (HER2) positive breast cancer.
MM-151
MM-151 is an oligoclonal therapeutic consisting of a mixture of three fully human monoclonal antibodies designed to bind to non-overlapping epitopes of the epidermal growth factor receptor (EGFR). EGFR is also known as ErbB1. An oligoclonal therapeutic is a mixture of two or more distinct monoclonal antibodies. The Company has designed MM-151 to block signal amplification that occurs within the ErbB cell signaling network. The Company has submitted an investigational new drug application (IND), to the FDA for MM-151 in July 2011.
Advisors' Opinion:- [By Keith Speights]
Not so merry
Merrimack Pharmaceuticals (NASDAQ: MACK ) shareholders have had reason to party since early May, with the stock surging more than 60%. The merriment came to a stop this week, though, as shares tanked by 27%. - [By John Udovich]
One way or the other, Merrimack Pharmaceuticals Inc (NASDAQ: MACK), Covidien plc (NYSE: COV), NeoGenomics, Inc (NASDAQ: NEO) and�CollabRx Inc (NASDAQ: CLRX) are targeting Barrett's Esophagus�or�esophageal cancer�(the former often leads to the latter) ��a form of cancer that may not be on the top of your list of cancers but is nevertheless on the rise. Approximately 3 million Americans suffer from Barrett's Esophagus, �a condition that�develops as a result of chronic injury from gastroesophageal reflux disease (GERD) where the�normal esophageal lining is replaced with abnormal cells (known as Barrett�� tissue), putting patients at greater risk of developing cancer of the esophagus. And although less than 1% of these patients develop cancer each year, esophageal carcinoma is frequently not detected until later stages, at which point therapy options are limited, extremely invasive, and often ineffective.�This means that�early detection is important�along with�regular surveillance is recommended.�
Top 10 Cheapest Stocks To Own For 2015: Nuvilex Inc (NVLX)
Nuvilex, Inc., incorporated on October 28, 1996, operates independently and through wholly owned subsidiaries. The Company is a biotechnology and life technology company with a specialty in living-cell encapsulation. It is focused on preparations for a new pancreatic cancer clinical trial through live-cell encapsulation of chemotherapeutic-converting cells. It has created the hardware and operating platform to envelop or encapsulate its own or other company's software products, or cells. These cells are then packaged in its live cell encapsulation operating system. Its products include Cinnechol, Cinnergen, Cinnsational, Citroxin, Cyclosurface, Cosmetics, Infinitink, Talsyn, Oraphyte and PurEffect. On July 10, 2013, the Company acquired Bio Blue Bird AG. In November 2013, the Company announced that it has acquired the exclusive worldwide rights to use the cellulose-based live-cell encapsulation technology for the development of treatments for diabetes from SG Austria Pte. Ltd.
Cinnechol
Cinnechol is a gluten free/wheat free all-natural supplement designed to help maintain normal cholesterol levels and support normal cardiovascular function through a healthy diet and regular exercise and to help individuals manage cardiovascular and metabolic disorders. Cinnechol may provide a natural alternative for those with high cholesterol and intolerant of, or elect not to take statins.
Cinnergen
Cinnergen is a gluten free/wheat free all-natural liquid whole food nutritional supplement that provides nutrients to help the body efficiently process glucose, is made from natural ingredients. Clinical studies using Cinnergen, as well as peer reviewed research suggest constituents of Cinnergen may help to reduce glucose absorption in the small intestine, limit glucose synthesis and increase its metabolism and prevent conditions associated with pre-diabetes or diabetes types one and two by delivering amino acids, vitamins, minerals, enzymes, antioxidants, and plant b! ased extracts to the body thus helping control glucose levels.
Cinnsational
Cinnsational is a gluten free/wheat free all-natural calorie-free, liquid nutritional supplement contains concentrated blend vitamins, essential amino acids, and other beneficial ingredients to help the body combat symptoms associated with alcohol sensitivity, including nausea, fatigue and headaches.
Citroxin
Citroxin is an all-natural, eco-friendly surface cleaner. Citroxin is protected by patents in the United States and Thailand.
Cyclosurface Cosmetics
Nuvilex�� Cyclosurface color enhancement technology provides formulators and manufacturers of cosmetics and other consumer products the ability to use less wax and other potentially detrimental additives in their products through a lipophilic surface treatment. It improves pigment dispersion enabling products that feel lighter on the skin and make the skin look radiant while maintaining or enhancing the color and durability of the cosmetic product.
I-Boost Immune Bar
I-Boost Immune Bar is a gluten free/wheat free all-natural nutritional bar designed to protect, stimulate, and boost the immune system. It was reformulated and contains a blend of vitamins, minerals, and other ingredients designed to enhance the body's natural ability to defend itself.
Infinitink
Infinitink is a permanent, yet removable tattoo ink, was engineered specifically for removal in fewer laser treatments than standard tattoo ink. Typically, lasers used for removal of tattoos use 532 and 1064 nanometer wavelengths which closely match the Infinitink tattoo pigments, enabling more easily removed tattoos.
Oraphyte
Oraphyte is the Company�� all-natural nematocide, is a non-toxic, biodegradable formulation that damages a nematode's skin surface, compromising its immune system, enabling it to be killed by the environment. In field tests, Oraphyte reduced! problema! tic nematodes, parasitic plant worms found in soil, compared to non-treated controls.
purEffect
PurEffect is a three part, all-in-one acne treatment designed to cleanse, tone, and heal skin combining ingredients to help maintain a radiant, blemish-free complexion. Benzoyl peroxide, the active ingredient in purEffect is the safest, recommended ingredient used to treat acne. This line of products completed pre-marketing testing by CK41.
Specialty, Private Label Inks
The Company has the potential to manufacture specialty inks for private label customers derived from the Company's Virgin and Infinitink product lines and are formulated to specific customer needs. The Company's specialty inks are formulated to be all natural, heavy metal and toxin-free.
Talsyn Scar Cream
Talsyn Scar Cream is a cream that delivers lipids, peptides, and botanical extracts to the skin. It was clinically proven to improve appearance of keloids, surgical incisions, and scars through decreasing their width, length, depth, and redness for both old and new scars. Talsyn Scar Cream has been endorsed and used by plastic and reconstructive surgeons.
Advisors' Opinion:- [By James E. Brumley]
Cancer drug investors who have been disappointed in recent results from shares of Clovis Oncology Inc. (NASDAQ:CLVS) or Nuvilex Inc. (OTCMKTS:NVLX) lately may want to take a look at ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as a replacement for either of those first two stocks. CLVS is down about 16% for the week on a less-than-flattering write-up in a Bloomberg publication, and NVLX has moved under a pair of key moving averages this week because, well, for no specific reason, but broadly because the recent wave of compelling news is already losing its potency, with most of that upside already being priced into shares (and then some) before it became official.
Top 10 Cheapest Stocks To Own For 2015: Hyundai Motor Co (HYMTF)
HYUNDAI MOTOR COMPANY is a Korea-based company principally engaged in the manufacture and distribution of automobiles and automobile parts. Along with its subsidiaries, the Company operates in three business divisions: vehicle division, financial division and other business division. Its vehicle division manufactures automobiles under the brand names of Genesis, Tucson, Equus, Veloster, Azera, Sonata, Elantra, Accent and others, and commercial vehicles, including trucks, buses, special vehicles and others, as well as provides automobile maintenance services and related components. Its financial division mainly provides automobile financing services and credit card services. Its other business division includes construction of railways and others. Advisors' Opinion:- [By John Rosevear]
Korean auto giant Hyundai (NASDAQOTH: HYMTF ) and its corporate cousin Kia (NASDAQOTH: KIMTF ) , which said �Wednesday that they would jointly recall over 1.8 million vehicles in the U.S. to fix a faulty brake-light switch, now say they will expand the recall globally.
Top 10 Cheapest Stocks To Own For 2015: SK Telecom Corporation Ltd.(SKM)
SK Telecom Co., Ltd. provides wireless telecommunications services using code division multiple access (CDMA) and wide-band CDMA technologies. It offers cellular voice services, such as wireless voice transmission services; and wireless global roaming services. The company also provides wireless data transmission services, such as wireless Internet access services, which allow subscribers to access online digital contents and services, as well as to send and receive text and multimedia messages. In addition, it offers broadband Internet and fixed-line telephone services, such as video-on-demand and IP TV services; and local, domestic, and international long-distance fixed-line telephone services to residential and commercial subscribers. Further, the company provides wireless entertainment-related contents and services, wireless finance-related contents and m-commerce services, and wireless news and search services; and international calling services, such as direct-dial, pre and post paid card calling services, bundled services for corporate customers, voice services using Internet protocol, Web-to-phone services, and data services. Additionally, it offers satellite digital media broadcasting services; telematics services; and fixed-line and online community portal services. The company also operates 11th Street, an online shopping mall; and T Store, an online open marketplace for mobile applications. As of March 31, 2011, SK Telecom Co. had 26 million wireless subscribers. It has strategic alliances with Bridge Alliance; Orange SA; Telecom Italia Mobile S.p.A.; T-Mobile International AG & Co; and Teliasonera Mobile Networks AB. The company was formerly known as Korea Mobile Telecommunications Co., Ltd. and changed its name to SK Telecom Co., Ltd. in March 1997. SK Telecom Co., Ltd. was founded in 1984 and is based in Seoul, South Korea.
Advisors' Opinion:- [By Garrett Cook]
Telecommunications services shares gained around 0.25 percent in today’s trading. Top gainers in the sector included NQ Mobile (NYSE: NQ), Nippon Telegraph and Telephone (NYSE: NTT), and SK Telecom Co (NYSE: SKM).
- [By Garrett Cook]
Telecommunications services shares gained around 0.25 percent in today’s trading. Top gainers in the sector included NQ Mobile (NYSE: NQ), Allot Communications (NASDAQ: ALLT), and SK Telecom Co (NYSE: SKM).
- [By Chris Neiger]
SK Telecom (NYSE: SKM ) launched the world's first 4G LTE-Advanced network in South Korea today, providing the fastest available data speeds for the same price as 4G LTE.�
- [By Garrett Cook]
Telecommunications services shares gained around 0.25 percent in today’s trading. Top gainers in the sector included NQ Mobile (NYSE: NQ), Allot Communications (NASDAQ: ALLT), and SK Telecom Co (NYSE: SKM).
Top 10 Cheapest Stocks To Own For 2015: Cliffs Natural Resources Inc.(CLF)
Cliffs Natural Resources Inc., a mining and natural resources company, produces iron ore pellets, lump and fines iron ore, and metallurgical coal products. The company operates six iron ore mines in Michigan, Minnesota, and eastern Canada; two iron ore mining complexes in Western Australia; five metallurgical coal mines located in West Virginia and Alabama; and one thermal coal mine located in West Virginia. It also owns a 45% economic interest in a coking and thermal coal mine located in Queensland, Australia; and a 30% interest in Amapa, a Brazilian iron ore project in Latin America, as well as chromite properties in Ontario, Canada. The company, formerly known as Cleveland-Cliffs Inc, was founded in 1847 and is headquartered in Cleveland, Ohio.
Advisors' Opinion:- [By Rick Munarriz]
Thursday
Cliffs Natural Resources (NYSE: CLF ) checks in on Thursday afternoon with its latest numbers, and they won't be pretty. The producer of iron ore and metallurgical coal is expected to post a double-digit percentage decline in revenue, and earnings are coming under even more pressure. - [By John Divine]
Lastly, iron ore and coal miner Cliffs Natural Resources (NYSE: CLF ) slumped 2.5% Friday. This stock has been an absolute nightmare for investors in the recent past, falling more than 80% in the last five years alone. But 2012, in particular, was a real doozy for the company, which went from turning a $1.6 billion profit the year before to hemorrhaging more than $930 million in the blink of an eye. Moving forward, the stock remains more than twice as volatile as the market, and until Cliffs can prove it's moving in the right direction, there's no particular reason to believe that volatility should be skyward. The July 25 earnings report would certainly be a good time to make the bullish case, though.
- [By Dan Caplinger]
Sinking like steel
The worst performer so far this year is Cliffs Natural Resources (NYSE: CLF ) , which plunged 57% in the first six months of 2013. The producer of iron ore and metallurgical coal has suffered from the big drop in demand for steel production, as key users like China and other emerging markets have seen their economies slow and the pace of their construction and infrastructure projects decelerate recently. Recent news of summer layoffs and the need for it to temporarily idle its Wabush Scully mine in Labrador because of forest fires are just the latest in a series of shutdowns and other measures that Cliffs has taken to try to stem the bleeding that required the company to slash its dividend by more than 75% earlier this year.